StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) income statement

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30473% above fair value
$95.05−0.06 (-0.06%)

Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –

Kiniksa Pharmaceuticals International, plc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
90.2%
Operating margin
13.8%
Net margin
11.6%
Return on equity, FY2025
11.7%

Financial strength

Current ratio
3.91
Debt to equity
–
Debt to assets
–
Cash to current liabilities
42.6%

Valuation

P/E ratio
73.1
Price to sales
15.79
Price to book
21.03
Dividend yield
–

See a number that looks wrong?